Table 7.

Univariate analysis of the survival rates according to histological risk factors.

Patients' groups		5-years DSS%	p	5-years OS%	p	5-years ORFS%	p	5-years LRFS%	p	5-years DMFS%	p
		SE		SE		SE		SE		SE
Previous RT	Naive patients	80.6	0.011	72.2	0.006	60.1	0.049	74	0.01	84.2	–
		11		6.7		7.3		9.5		6.5
	Previous RT	0		0		0		0		–
		0		0		0		0
Stage AJCC 2017	All patients
	I	100	0.0002	42	0.002	100	0.003	100	0.02	100	0.07
		0		30.4		0		0		0
	II	93.8		80.4		86.5		86.5		100
		6.1		10.7		8.9		8.9		0
	III	79.5		79.5		51.3		55.6		77.9
		11.9		11.9		15.2		15.9		10
	IV	42.9		41.2		42.9		50.7		76.1
		11.9		11.5		11.9		13.1		9.4
	Naive patients
	I	100	0.0031	40	0.0135	100	0.0383	100	0.1494	100	0.1109
		0		29.7		0		0		0
	II	100		94.7		91.7		91.7		100
		0		5.1		7.8		8		0
	III	89.9		89.9		56		61.6		75
		6.7		6.8		15.5		16		11.2
	IV	55.9		53.6		55.9		66.1		76.1
		11.7		11.4		11.7		12.2		9.4
pN	All patients
	0	86.9	0.0001	72.5	0.0001	72.4	0.0001	72.4	0.0001	97.2	0.0001
		6.6		9.1		9.3		9.3		2.7
	1	53		53		53		53		63.6
		23.3		23.3		23.3		23.3		17.7
	2	52.8		49.9		63.3		63.3		76.9
		13.2		12.8		13.6		13.6		11.7
	3	0		0		0		0		0
		0		0		0		0		0
	Naive patients
	0	97.5	<0.0001	86	<0.0001	81.2	<0.0001	81.2	<0.0001	96.9	<0.0001
		2.5		7.2		8.4		8.4		3.1
	2	53		53		42.4		53		63.6
		23.3		23.3		21		23.3		17.7
	3	61.2		57.4		61.3		74.9		75
		13.8		13.4		13.8		13		12.5
	4	0		0		0		0		0
		0		0		0		0		0
LNR	All patients
	0	92.1	<0.0001	76.5	<0.0001	74.5	<0.0001	74.5	<0.0004	97.1	<0.0001
		4.4		8.6		8.8		8.8		2.8
	≤ 0.09	54		52.2		49		61		70.1
		11.6		11.3		11.5		12		10.6
	>0.09	0		0		0		0		33.3
		0		0		0		0		27.2
	Naive patients
	0	97.4	<0.0001	85.9	<0.0001	81.1	<0.0001	81.1	<0.0001	96.9	<0.0001
		2.5		7.2		8.4		8.4		3
	≤0.09	63		60.7		57.2		72		68
		12		11.8		12.2		12		11
	>0.09	0		0		0		0		33.3
		0		0		0		0		27.2
Grading	All patients
	1	80.5	0.6	68.6	0.8	80.5	0.1	80.5	0.3	96.3	0.14
		7.9		9.4		7.9		7.9		3.6
	2	60.1		58.5		37.8		44.1		75.2
		13.1		12.9		14.2		16.1		8.5
	3	83.3		55.6		69.4		76.4		90.1
		10.8		23.8		15.5		15.5		8.7
	Naive patients
	1	82.3	0.8265	74.8	0.9927	82.3	0.2765	82.3	0.5431	95.8	0.1543
		8.2		8.9		8.2		8.2		4.1
	2	78.6		76.4		52.6		61.7		73.5
		7.9		8		14		15.4		8.9
	3	90.9		90.9		75.8		83.3		90.9
		8.7		8.7		15.6		15.2		8.7
PNI	All patients
	Absent	78.7	0.07	68	0.08	71.6	0.006	71.6	0.17	91.5	0.53
		6.6		7.8		7.9		7.9		4.1
	Present	63.1		60.5		43.8		59		72.3
		11.5		11.3		12.8		14.4		11
	Naive patients
	Absent	83.9	0.3313	75.8	0.2963	76.6	0.0271	76.6	0.6917	90.9	0.0285
		5.7		7		7.4		7.4		4.4
	Present	76.4		72.6		49.3		70.3		67.2
		10.4		10.6		15		17		12.7
LVI	All patients
	Absent	84.5	0.001	71.9	0.004	73.5	0.0008	73.5%	0.04	98%	0.0001
		6.2		8.2		8.6		8.6		2
	Present	48.3		46.5		38.7		51.9		59.1
		12.7		12.3		11.9		13.7		11.6
	Naive patients
	Absent	91	0.0028	81.3%	0.008	79.5%	0.0019	79.5%	0.1241	97.8%	<0.0001
		4.3		6.9		7.8		7.8		2.2
	Present	53.4		50.8		41.5		59		52.2
		14.9		14.4		13.8		16.2		12.7
PNI-LVI	All patients
	Absent	82.4	0.002	69.3	0.002	76.1	0.0013	76.1	0.06	97.5	0.0006
		6.8		8.6		8.8		8.8		2.5
	Both present	42.7		39.9		32.1		57.9		53.7
		14.8		14.1		14.4		17.2		16.2
	Naive patients
	Absent	85.9	0.0081	78.1%	0.0036	74.7%	0.0033	74.7%	0.9396	92.9%	<0.0001
		5.1		16.6		7.2		7.2		3.8
	Both present	56.3		51.1		37.5		87.5		37.5
		16.5		15.8		18.9		11.7		18.9

DSS, Disease-specific Survival; LRFS, Local Relapse-free Survival; ORFS, Overall Relapse-free Survival; DMFS, Distant Metastasis-free Survival; OS, Overall Survival; PNI, Perineural Invasion; LVI, Lymphovascular Invasion; LNR, Lymph node ratio.